AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure Inc. reported fourth-quarter revenues of $124.3 million, reflecting a year-over-year increase of 16.6%, which surpassed expectations by approximately $4 million. The company's research and development expenses represented 28.1% of sales, up significantly year-over-year, driven by a notable $12 million upfront payment for a co-development agreement, indicating robust investment in innovation. Additionally, an EBITDA margin of 10.2% marked a substantial improvement of 570 basis points year-over-year, signalling positive trends in profitability and operational efficiency that contribute to a favorable long-term outlook for the company.
Bears say
AtriCure faces several financial risks, including disappointing sales from its EPi-Sense/Convergent products and expectations of lower revenues from Open Ablation and AtriClip sales, contributing to a negative outlook. The company's revenue growth is projected to decrease to under 11%, with notable slowdowns in key segments such as Minimally Invasive Ablation, Appendage Management, and Pain Management, compounded by competition from Medtronic's LAA device. Furthermore, AtriCure's gross and operating margins have both declined year-over-year, indicating unfavorable trends in profitability despite a slight improvement in adjusted EBITDA margin.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares